Literature DB >> 19562292

The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure.

Mitja Lainscak1, Lea Majc Hodoscek, Hans-Dirk Düngen, Mathias Rauchhaus, Wolfram Doehner, Stefan D Anker, Stephan von Haehling.   

Abstract

OBJECTIVES: Like chronic heart failure, chronic obstructive pulmonary disease (COPD) is an enormous public health problem in industrialized countries. Our aim was to determine the prevalence and clinical impact of COPD among patients hospitalized for heart failure in a community hospital serving a population of 125,000 people.
METHODS: Between 2001 and 2003 a total of 638 patients (73 +/- 10 years, 48% men, 74% NYHA class III) were identified with a discharge diagnosis of heart failure. Medical charts were reviewed and vital status was obtained from a Central Population Registry.
RESULTS: COPD was diagnosed in 106 (17%) patients whose age was similar to those without COPD (73 +/- 9 vs. 73 +/- 11 years, P = 0.35). Patients with COPD were more often males (65% vs. 45%, P < 0.001). There were no differences in arterial hypertension, atrial fibrillation, diabetes mellitus and most laboratory markers except hemoglobin (141 +/- 20 vs. 132 +/- 20 g/l, P < 0.001) and uric acid (453 +/- 136 vs. 414 +/- 139 mmol/l, P = 0.013). At discharge, patients with COPD were less likely to receive beta-blockers (12% vs. 28%, odds ratio 0.35, 95% CI0.19-0.64). During follow-up, patients with COPD had higher mortality (73% vs. 60%, P = 0.016, hazard ratio 1.48, 95% CI 1.15-1.90). Kaplan-Meier (log-rank test, P = 0.002) and Cox proportional hazard analysis, adjusted for age, sex, hemoglobin, uric acid, and treatment with beta-blockers and furosemide (hazard ratio 1.38, 95% CI1.04-1.83, P = 0.024) demonstrated the prognostic importance of COPD.
CONCLUSIONS: COPD is frequent among hospitalized patients with heart failure. Beta-blockers are largely underused, which is probably a major reason for the higher mortality observed in patients with concomitant chronic heart failure and COPD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19562292     DOI: 10.1007/s00508-009-1185-8

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  34 in total

1.  [Why heart failure clinics?].

Authors:  Martin Hülsmann; Richard Pacher
Journal:  Wien Klin Wochenschr       Date:  2002-10-31       Impact factor: 1.704

2.  Ghrelin and neurohumoral antagonists in the treatment of cachexia associated with cardiopulmonary disease.

Authors:  Mitja Lainscak; Stefan Andreas; Paul D Scanlon; Virend K Somers; Stefan D Anker
Journal:  Intern Med       Date:  2006-08-01       Impact factor: 1.271

3.  Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers.

Authors:  Mitja Lainscak; Stephan von Haehling; Stefan D Anker
Journal:  Int J Cardiol       Date:  2009-01-13       Impact factor: 4.164

4.  Patients' knowledge and beta blocker treatment improve prognosis of patients from a heart failure clinic.

Authors:  Mitja Lainscak; Irena Keber
Journal:  Eur J Heart Fail       Date:  2005-09-26       Impact factor: 15.534

5.  Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging.

Authors:  Stefan D Anker; Wolfram Doehner; Mathias Rauchhaus; Rakesh Sharma; Darrel Francis; Christoph Knosalla; Constantinos H Davos; Mariantonietta Cicoira; Waqar Shamim; Michel Kemp; Robert Segal; Karl Josef Osterziel; Francisco Leyva; Roland Hetzer; Piotr Ponikowski; Andrew J S Coats
Journal:  Circulation       Date:  2003-04-21       Impact factor: 29.690

6.  Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases.

Authors:  Matthias John; Andre Lange; Soeren Hoernig; Christian Witt; Stefan D Anker
Journal:  Int J Cardiol       Date:  2005-10-19       Impact factor: 4.164

Review 7.  State of the art: using natriuretic peptide levels in clinical practice.

Authors:  Alan Maisel; Christian Mueller; Kirkwood Adams; Stefan D Anker; Nadia Aspromonte; John G F Cleland; Alain Cohen-Solal; Ulf Dahlstrom; Anthony DeMaria; Salvatore Di Somma; Gerasimos S Filippatos; Gregg C Fonarow; Patrick Jourdain; Michel Komajda; Peter P Liu; Theresa McDonagh; Kenneth McDonald; Alexandre Mebazaa; Markku S Nieminen; W Frank Peacock; Marco Tubaro; Roberto Valle; Marc Vanderhyden; Clyde W Yancy; Faiez Zannad; Eugene Braunwald
Journal:  Eur J Heart Fail       Date:  2008-08-29       Impact factor: 15.534

8.  Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma.

Authors:  Eugene Kotlyar; Anne M Keogh; Peter S Macdonald; Ruth H Arnold; Dermot J McCaffrey; Allan R Glanville
Journal:  J Heart Lung Transplant       Date:  2002-12       Impact factor: 10.247

9.  The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis.

Authors:  J G F Cleland; K Swedberg; F Follath; M Komajda; A Cohen-Solal; J C Aguilar; R Dietz; A Gavazzi; R Hobbs; J Korewicki; H C Madeira; V S Moiseyev; I Preda; W H van Gilst; J Widimsky; N Freemantle; Joanne Eastaugh; J Mason
Journal:  Eur Heart J       Date:  2003-03       Impact factor: 29.983

10.  Challenges of beta blocker therapy in chronic heart failure: the story continues.

Authors:  Mitja Lainscak; Jerneja Farkas
Journal:  Eur J Cardiovasc Nurs       Date:  2008-03-26       Impact factor: 3.908

View more
  24 in total

1.  COPD is not COPD is not allergy.

Authors:  Stanislav Suskovic
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 2.  Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review.

Authors:  Wolfram Doehner; Stephan von Haehling; Stefan D Anker; Mitja Lainscak
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 3.  Heart failure management in the elderly - a public health challenge.

Authors:  Natasa Cvetinovic; Goran Loncar; Jerneja Farkas
Journal:  Wien Klin Wochenschr       Date:  2016-11-29       Impact factor: 1.704

4.  Challenges of Treating Acute Heart Failure in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Jelena Čelutkienė; Mindaugas Balčiūnas; Denis Kablučko; Liucija Vaitkevičiūtė; Jelena Blaščiuk; Edvardas Danila
Journal:  Card Fail Rev       Date:  2017-04

5.  Heart failure and chronic obstructive pulmonary disease: Two for tea or tea for two?

Authors:  Stanislav Suskovic; Mitja Kosnik; Mitja Lainscak
Journal:  World J Cardiol       Date:  2010-10-26

Review 6.  The cardiorenal syndrome in heart failure: cardiac? renal? syndrome?

Authors:  Filippos Triposkiadis; Randall C Starling; Harisios Boudoulas; Gregory Giamouzis; Javed Butler
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

7.  Short-term outcomes in heart failure patients with chronic obstructive pulmonary disease in the community.

Authors:  Noel O'Kelly; William Robertson; Jude Smith; Jonathan Dexter; Collette Carroll-Hawkins; Sudip Ghosh
Journal:  World J Cardiol       Date:  2012-03-26

8.  Mortality and readmissions in heart failure: an analysis of 36,824 elderly patients from the Slovenian national hospitalization database.

Authors:  Daniel Omersa; Mitja Lainscak; Ivan Erzen; Jerneja Farkas
Journal:  Wien Klin Wochenschr       Date:  2016-10-19       Impact factor: 1.704

9.  Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure.

Authors:  Qiaojun Zeng; Shanping Jiang
Journal:  J Thorac Dis       Date:  2012-06-01       Impact factor: 2.895

10.  The prognostic significance of lung function in stable heart failure outpatients.

Authors:  Louis Lind Plesner; Morten Dalsgaard; Morten Schou; Lars Køber; Jørgen Vestbo; Erik Kjøller; Kasper Iversen
Journal:  Clin Cardiol       Date:  2017-09-13       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.